CD19 and neoplasm: However, the anti-tumor effects of the LAG-3 knockout CD19 CAR-T cells were similar to standard CAR-T cells, probably indicating that LAG-3 is not the primary checkpoint by which lymphoma cells induce T cell exhaustion [98].